TY - JOUR T1 - Aliskiren: clinical experience and future perspectives of renin inhibition. AU - Sureshkumar,Kalathil K, AU - Vasudevan,Sapna, AU - Marcus,Richard J, AU - Hussain,Sabiha M, AU - McGill,Rita L, PY - 2008/3/19/pubmed PY - 2008/4/11/medline PY - 2008/3/19/entrez SP - 825 EP - 37 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 9 IS - 5 N2 - BACKGROUND: Aliskiren, the first renin inhibitor with sufficient bioavailability for oral use, is now available to clinicians treating hypertension. OBJECTIVE: The novel mechanism by which aliskiren works was used to provide understanding of its therapeutic and adverse effects. METHODS: After reviewing physiology and preclinical studies, human studies of aliskiren in hypertension were reviewed. Effects of aliskiren on serum levels and enzymatic activity of renin were explored. RESULTS/CONCLUSIONS: Aliskiren has antihypertensive efficacy similar to existing medications such as thiazide diuretics, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and can be used in drug combinations. Preclinical studies indicate possible cardioprotective and renoprotective effects, similar to other inhibitors of the renin-angiotensin cascade, but future studies are needed in humans. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/18345958/Aliskiren:_clinical_experience_and_future_perspectives_of_renin_inhibition_ L2 - https://www.tandfonline.com/doi/full/10.1517/14656566.9.5.825 DB - PRIME DP - Unbound Medicine ER -